On April 22, 2026 Oxford Vacmedix (OVM), the UK biotech company developing novel immunotherapies to treat cancer, reported the successful completion of the Phase 1 trial of OVM-200. The primary endpoint for safety has been met as well as the secondary endpoints for immune response and dose selection. In addition, there are early observations of clinical efficacy in NSCLC and in prostate cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This Phase 1 clinical trial of OVM-200 is a multicentre, open‑label, first‑in‑human evaluation of OVM‑200, an immunotherapy developed using Oxford Vacmedix’s Recombinant Overlapping Peptide (ROP) therapeutic platform. 36 Patients with advanced NSCLC (non‑small cell lung cancer), ovarian cancer, or prostate cancer and with no HLA restrictions, were treated in the trial. The results show:

Excellent Safety Profile (primary endpoint): OVM‑200 is very well tolerated with no serious adverse drug reactions or no dose‑limiting toxicities. The only adverse effects were Grade 1 injection‑site reactions.
Very strong Immunogenicity (secondary endpoint): the immune response for both antibodies and for T cells were very strong even in an advanced Stage IV patient population. The immune responses data conclusively demonstrates the dual mode of action of the ROP technology.
Therapeutic Dose established (secondary endpoint) based on the immune response, the 2mg dose was chosen for Phase 1b with expanded immunisations of up to 11 doses of 2mg being used.
Early observations of clinical efficacy with stable disease in NSCLC and PSA response in prostate cancer.
Professor Shisong Jiang, founder and Chief Scientific Officer of Oxford Vacmedix, said:

We are delighted to be able to confirm these results for this Phase 1 trial of OVM-200 and with this first step toward providing accessible immunotherapy for all patient types. This progress has only been possible through the participation of the patients in the trial and the dedication of the staff in the clinics.

William Finch, Chief Executive Officer of Oxford Vacmedix, said:

This completion of the clinical trial of OVM-200 marks an important milestone for the company and shows the potential of the ROP technology. We are very pleased to have reached this significant inflection point and are already in discussion with Series B investors to fund Phase 2 trials for OVM-200.

(Press release, Oxford Vacmedix, APR 22, 2026, View Source;utm_medium=rss&utm_campaign=successful-ovm-200-phase-1-trial [SID1234664686])